CDKN2A and neoplasm: Since a previous study did not report a difference in survival between Arf+/+p53−/− and Arf−/−p53−/− mice [12], we questioned whether the accelerated tumor development in p53−/− mice with loss of Arf was somehow due to the Mdm2 heterozygosity.